J Thorac Dis. 2019 Jan;11(Suppl 1):S81-S88. doi: 10.21037/jtd.2019.01.46.

Update on emerging biomarkers in lung cancer.

Bernicker EH1, Allen TC2, Cagle PT3.

Author information

1

Houston Methodist Hospital, Cancer Center, Houston, Texas, USA.

2

Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi, USA.

3

Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA.

Abstract

There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.